DiaSorin S.p.A. (OTCMKTS:DSRLF) Given Average Recommendation of “Hold” by Analysts

Shares of DiaSorin S.p.A. (OTCMKTS:DSRLF) have been assigned a consensus rating of “Hold” from the six brokerages that are presently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company.

A number of brokerages have issued reports on DSRLF. Zacks Research upgraded shares of DiaSorin to a “hold” rating in a research note on Tuesday, May 12th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of DiaSorin in a research note on Tuesday, February 10th. Finally, UBS Group downgraded shares of DiaSorin from a “buy” rating to a “neutral” rating in a report on Thursday, April 9th.

DiaSorin Stock Performance

Shares of DiaSorin stock opened at $84.10 on Monday. DiaSorin has a 12-month low of $66.50 and a 12-month high of $112.30. The firm’s 50 day simple moving average is $69.53 and its two-hundred day simple moving average is $74.67.

DiaSorin Company Profile

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.